Analyst Reco. Cardlytics, Inc.

Equities

CDLX

US14161W1053

Real-time Estimate Cboe BZX Other stock markets 17:52:56 03/05/2024 BST			5-day change	1st Jan Change
14.89 ^USD	+6.59%		+21.85%	+62.87%

04-25	Cardlytics Insider Sold Shares Worth $278,885, According to a Recent SEC Filing	MT
04-09	Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cardlytics Insider Sold Shares Worth $278,885, According to a Recent SEC Filing	04-25	MT
Needham Raises Cardlytics' Price Target to $17 From $15, Maintains Buy Rating	04-09	MT
Cardlytics Insider Sold Shares Worth $448,020, According to a Recent SEC Filing	04-03	MT
Craig-Hallum Upgrades Cardlytics to Buy From Hold, Adjusts Price Target to $18 From $10	03-15	MT
Lake Street Adjusts Cardlytics' Price Target to $18 From $13, Maintains Buy Rating	03-15	MT
Lake Street Starts Coverage on Cardlytics with Buy Rating, $13 Price Target	11-29	MT
Needham Adjusts Price Target on Cardlytics to $19 From $10, Maintains Buy Rating	02/08/23	MT
Needham Adjusts Price Target on Cardlytics to $10 From $8, Maintains Buy Rating	05/05/23	MT
Wells Fargo Adjusts Price Target on Cardlytics to $6 From $5, Keeps Underweight Rating	12/04/23	MT
JPMorgan Adjusts Cardlytics Price Target to $6 From $7, Maintains Neutral Rating	02/03/23	MT
Wells Fargo Adjusts Price Target on Cardlytics to $5 From $6, Keeps Underweight Rating	02/03/23	MT
Needham Lowers Price Target on Cardlytics to $8 From $14, Maintains Buy Rating	02/03/23	MT
Wells Fargo Adjusts Price Target on Cardlytics to $6 From $10, Maintains Underweight Rating	09/01/23	MT
Needham Adjusts Price Target on Cardlytics to $14 From $19, Maintains Buy Rating	02/11/22	MT
Wells Fargo Adjusts Cardlytics Price Target to $10 From $13, Maintains Underweight Rating	02/11/22	MT
Wells Fargo Downgrades Cardlytics to Underweight From Equalweight, Trims Price Target to $13 From $14	08/09/22	MT
Wells Fargo Trims Cardlytics Price Target to $14 From $15, Maintains Equalweight Rating	03/08/22	MT
Needham Adjusts Cardlytics' Price Target to $19 From $24, Reiterates Buy Rating	03/08/22	MT
Wells Fargo Downgrades Cardlytics to Equalweight From Overweight, Adjusts Price Target to $15 From $72	14/07/22	MT
Needham Adjusts Cardlytics' Price Target to $24 from $60, Keeps Buy Rating	13/07/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Cardlytics, Inc.

Equities

CDLX

US14161W1053

Analyst Reco.

Filters